ADBIOTECH Posts Q1 Consolidated Operating Loss of 1.06B Won and Net Loss of 5.4B Won, Impacted by CB Valuation Losses

Consolidated revenue decreased 11% YoY to 3.07 billion won, and operating loss widened to 1.06 billion won from 0.2 billion won loss in the prior year period
Consolidated net loss attributable to controlling interest surged to 5.40 billion won from 0.60 billion won loss a year ago, mainly due to financial costs of 5.94 billion won including valuation losses on convertible bonds (3.0 billion won) and disposal losses (2.15 billion won)
Debt ratio improved to 213.64% from 257.52% at year-end, aided by equity increase (33.2 billion won paid-in capital increase) and redemption of convertible bonds
No shareholder return events such as dividends or share buybacks/cancellations during the period
Issued 3,319,251 common shares (par value 500 won) via a third-party allotment to BK Partners Investment Association No. 2 in January 2026, increasing capital by 1.66 billion won
Cash and cash equivalents increased to 4.94 billion won from 3.91 billion won at year-end; operating cash flow was positive at 1.67 billion won
Accumulated deficit reached 33.10 billion won on a consolidated basis; not in capital impairment but the deficit remains large

ADVERTISEMENT (250px+)